New antibody drug targets Hard-to-Treat cancers
NCT ID NCT07678970
First seen Jul 01, 2026 · Last updated Jul 17, 2026 · Updated 3 times
Summary
This early-stage trial tests a new drug called SI-B036, a bispecific antibody designed to fight advanced gastrointestinal and other solid tumors. The study involves about 16 adults with tumors that have spread or cannot be removed. Researchers aim to find a safe dose and see if the drug shows any signs of shrinking tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SI-B036 (bispecific antibody)
- What this could lead to
- If successful, this could point toward a new treatment option for advanced gastrointestinal and other solid tumors.
- What could go wrong
- This is an early Phase I trial with only 16 participants, so safety and dosing are the main focus. The drug may not show anti-tumor activity or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can a Tumor's DNA guide better cancer care for kids?
- Can a new PET tracer reveal a key cancer target?
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a new tracer light up cancer growth?
- Can a Dual-Pronged antibody outsmart advanced cancers?